JP2005047904A - External preparation composition - Google Patents

External preparation composition Download PDF

Info

Publication number
JP2005047904A
JP2005047904A JP2004207104A JP2004207104A JP2005047904A JP 2005047904 A JP2005047904 A JP 2005047904A JP 2004207104 A JP2004207104 A JP 2004207104A JP 2004207104 A JP2004207104 A JP 2004207104A JP 2005047904 A JP2005047904 A JP 2005047904A
Authority
JP
Japan
Prior art keywords
particle size
average particle
lamella
vesicle
lamellar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004207104A
Other languages
Japanese (ja)
Other versions
JP4592347B2 (en
Inventor
Takashi Kinoshita
貴史 木下
Hiroshi Tsukamoto
浩史 塚本
Satoshi Yoshikawa
聡 吉川
Toshiro Sone
俊郎 曽根
Riyouko Iizuka
量子 飯塚
Katsuyoshi Chiba
勝由 千葉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP2004207104A priority Critical patent/JP4592347B2/en
Publication of JP2005047904A publication Critical patent/JP2005047904A/en
Application granted granted Critical
Publication of JP4592347B2 publication Critical patent/JP4592347B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide an external preparation excellent in preventing effect on skin-aging. <P>SOLUTION: The subject external preparation composition contains a lamella vehicle having 0.05-5μm average particle size and a lamella vehicle having 6-30μm average particle size. The lamella vehicles comprise fatty acid monoglycerides as their principal ingredients. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

本発明は、皮膚の肥厚や弾力性の低下を抑制する効果に優れた外用剤組成物に関する。   The present invention relates to an external preparation composition excellent in the effect of suppressing skin thickening and elasticity reduction.

ヒトの皮膚は、紫外線や加齢とともに肥厚や弾力性の低下が進行し、その結果としてしわ、たるみ、くすみ等が生じる。かかる皮膚の老化に対して、合成又は天然の保湿成分、種々の植物抽出物、ルチン糖誘導体、セリシン等の蛋白質、α−ヒドロキシ酸等を配合した化粧料が提案されている。
また、脂肪酸モノグリセリドを主成分とするラメラ構造体(特許文献1)、脂肪酸モノグリセリドを主成分とするラメラ構造体とビタミンAを含有する皮膚外用剤(特許文献2)及び脂肪酸モノグリセリドを主成分とするラメラ構造体とそのラメラ構造体に内包されたアスコルビン酸を含有する皮膚外用剤(特許文献3)が優れた保湿作用や老化防止効果を有することが知られている。
特許第2606761号公報 特開2000−239140号公報 特開2002−145751号公報
Human skin undergoes thickening and a decrease in elasticity with ultraviolet rays and aging, resulting in wrinkles, sagging, dullness, and the like. For such skin aging, cosmetics containing synthetic or natural moisturizing ingredients, various plant extracts, rutin sugar derivatives, proteins such as sericin, α-hydroxy acids and the like have been proposed.
Moreover, the lamellar structure which has a fatty acid monoglyceride as a main component (patent document 1), the lamellar structure which has a fatty acid monoglyceride as a main component, and the skin external preparation containing vitamin A (patent document 2), and a fatty acid monoglyceride as a main component It is known that a skin external preparation (Patent Document 3) containing a lamellar structure and ascorbic acid encapsulated in the lamellar structure has excellent moisturizing action and anti-aging effect.
Japanese Patent No. 2606761 JP 2000-239140 A JP 2002-145751 A

しかしながら、これらのラメラ構造体の効果は未だ十分満足すべきものではなく、さらに皮膚老化防止効果に優れた外用剤素材が求められている。   However, the effects of these lamella structures are not yet satisfactory, and there is a demand for an external preparation material that is further excellent in the effect of preventing skin aging.

そこで本発明者らは皮膚の老化防止効果に優れた素材を探索してきたところ、全く意外にも、平均粒子径の大きな脂肪酸モノグリセリドを主成分とするラメラベシクルと平均粒子径の小さな脂肪酸モノグリセリドを主成分とするラメラベシクルとを併用すると、極めて顕著な皮膚の肥厚抑制効果及び弾力性低下抑制効果が得られることを見出し、本発明を完成した。   Thus, the present inventors have searched for a material excellent in the effect of preventing skin aging, and surprisingly, mainly, a lamellar vesicle mainly composed of a fatty acid monoglyceride having a large average particle diameter and a fatty acid monoglyceride having a small average particle diameter are mainly used. It has been found that when a lamellar vesicle as a component is used in combination, extremely remarkable skin thickening suppression effect and elasticity reduction suppression effect can be obtained, and the present invention has been completed.

また、平均粒子径の小さなラメラベシクルの製造法についても検討した結果、脂肪酸モノグリセリドを含む脂質成分を特定の濃度範囲で用い、油相に水相を添加することにより、簡便な操作で粒度分布の狭い平均粒子径0.05〜1μmの微小ラメラベシクルが効率良く得られることを見出した。   In addition, as a result of studying the production method of lamellar vesicles with a small average particle diameter, the lipid component containing fatty acid monoglyceride was used in a specific concentration range, and the water phase was added to the oil phase, so that the particle size distribution could be easily operated. It has been found that fine lamella vesicles having a narrow average particle diameter of 0.05 to 1 μm can be obtained efficiently.

すなわち、本発明は、脂肪酸モノグリセリドを主成分とするラメラベシクルであって、平均粒子径0.05〜5μmのラメラベシクルと平均粒子径6〜30μmラメラベシクルとを含有することを特徴とする外用剤組成物を提供するものである。
また、本発明は、脂肪酸モノグリセリドを主成分とする脂質成分20〜40重量部に水相成分60〜80重量部を添加して撹拌することを特徴とする平均粒子径0.05〜1μmのラメラベシクルの製造法を提供するものである。ここでいう、平均粒子径とは、粒度分布から求められた粒子径の中央値(メジアン)をいう。
That is, the present invention is a lamellar vesicle mainly composed of a fatty acid monoglyceride and containing a lamellar vesicle having an average particle size of 0.05 to 5 μm and a lamellar vesicle having an average particle size of 6 to 30 μm. A composition is provided.
The present invention also provides a lamella having an average particle diameter of 0.05 to 1 μm, wherein 60 to 80 parts by weight of an aqueous phase component is added to 20 to 40 parts by weight of a lipid component mainly composed of a fatty acid monoglyceride and stirred. A method for producing vesicles is provided. Here, the average particle size refers to the median value (median) of the particle sizes obtained from the particle size distribution.

本発明の外用剤組成物は、優れた皮膚の肥厚抑制効果や皮膚弾力性の改善効果を示し、総合的な皮膚の改善に有用である。さらに皮膚に対する刺激性もなく、これを用いることで優れた皮膚化粧料を得ることができる。   The external preparation composition of the present invention exhibits an excellent effect of suppressing skin thickening and improving skin elasticity, and is useful for comprehensive skin improvement. Furthermore, there is no irritation | stimulation with respect to skin, By using this, the outstanding skin cosmetics can be obtained.

本発明に用いるラメラベシクルの主成分は、脂肪酸モノグリセリドであるが、保湿効果、トランスグルタミナーゼ1活性化効果、皮膚の肥厚及び弾力性低下抑制効果の点から、特に炭素数8〜20の飽和又は不飽和脂肪酸モノグリセリドが好ましい。脂肪酸モノグリセリドの構成脂肪酸の具体例としては、カプリル酸、カプリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、オレイン酸、パルミトオレイン酸等が挙げられ、これらのモノグリセリドは2種以上のものを組み合わせて用いてもよい。特に平均粒子径0.05〜1μmの小さなラメラベシクルを得ようとする場合には、モノパルミチン酸を構成脂肪酸とする脂肪酸モノグリセリドを用いることで、平均粒子径が0.05〜1μm、より好ましくは0.1〜1μmで、かつほぼ均一の粒子径の微粒子ラメラベシクルを得ることができる。これに組み合わせるモノグリセリドとしては、その脂肪酸組成がステアリン酸、ミリスチン酸であるものが好ましい。   The main component of the lamellar vesicle used in the present invention is a fatty acid monoglyceride. However, from the viewpoint of moisturizing effect, transglutaminase 1 activation effect, skin thickening, and elasticity reduction inhibiting effect, it is particularly saturated or unsaturated with 8 to 20 carbon atoms. Saturated fatty acid monoglycerides are preferred. Specific examples of constituent fatty acids of fatty acid monoglycerides include caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, palmitooleic acid, etc., and these monoglycerides are of two or more types May be used in combination. In particular, when trying to obtain a small lamella vesicle having an average particle size of 0.05 to 1 μm, the average particle size is 0.05 to 1 μm, more preferably by using a fatty acid monoglyceride having monopalmitic acid as a constituent fatty acid. Fine lamella vesicles having a particle diameter of 0.1 to 1 μm and a substantially uniform particle diameter can be obtained. As the monoglyceride to be combined therewith, it is preferable that the fatty acid composition is stearic acid or myristic acid.

また、このラメラベシクルの他の構成成分としては、コレステロール、アルキル又はアルケニルモノグリセリンエーテル等が挙げられる。コレステロールの配合は、ラメラベシクルの安定性を向上させるため、特に好ましい。アルキル又はアルケニルモノグリセリンエーテルとしては、炭素数8〜20のアルキル又はアルケニルモノグリセリンエーテルが好ましい。これらコレステロールやモノグリセリンエーテルの添加量は、合計で脂肪酸モノグリセリド100重量部に対し、1〜100重量部、特に5〜25重量部が好ましい。   Moreover, cholesterol, an alkyl, or an alkenyl monoglycerol ether etc. are mentioned as another structural component of this lamella vesicle. Cholesterol is particularly preferred because it improves the stability of the lamellar vesicles. As the alkyl or alkenyl monoglycerin ether, an alkyl or alkenyl monoglycerin ether having 8 to 20 carbon atoms is preferable. The total amount of cholesterol and monoglycerin ether added is preferably 1 to 100 parts by weight, particularly 5 to 25 parts by weight, based on 100 parts by weight of the fatty acid monoglyceride.

本発明においては、このような脂肪酸モノグリセリドを主成分とするラメラベシクルであって、平均粒子径0.05〜5μmのラメラベシクルと平均粒子径6〜30μmのラメラベシクルとを併用することを特徴とする。好ましい組み合せは平均粒子径0.05〜5μmのラメラベシクルと6〜20μmのラメラベシクルで、特に好ましい組み合わせは平均粒子径0.1〜5μmのラメラベシクルと6〜20μmのラメラベシクルである。これら粒子径の異なる2種のラメラベシクルを併用することにより、それぞれ単独の作用からは全く予想し得ない程優れた皮膚肥厚抑制効果及び皮膚の弾力性低下抑制効果が得られる。   In this invention, it is a lamella vesicle which has such a fatty acid monoglyceride as a main component, Comprising: The lamella vesicle with an average particle diameter of 0.05-5 micrometers and the lamella vesicle with an average particle diameter of 6-30 micrometers are used together. To do. A preferred combination is a lamellar vesicle having an average particle size of 0.05 to 5 μm and a lamellar vesicle having an average particle size of 6 to 20 μm, and a particularly preferred combination is a lamellar vesicle having an average particle size of 0.1 to 5 μm and a lamellar vesicle having 6 to 20 μm. By using these two types of lamellar vesicles having different particle diameters in combination, it is possible to obtain a skin thickening inhibitory effect and a skin elasticity reduction inhibitory effect which are so excellent that they cannot be predicted at all from a single action.

このような平均粒子径の異なるラメラベシクルは、粒度分布の広いラメラベシクルを調製した後、ゲルろ過や遠心分離、異なるポアサイズのろ過膜を用いて逐次ろ過することにより製造することもできるが、それぞれ別途に製造してもよい。   Such lamellar vesicles with different average particle diameters can be produced by preparing lamellar vesicles with a wide particle size distribution, followed by gel filtration, centrifugation, and successive filtration using filtration membranes of different pore sizes. It may be manufactured separately.

かかるラメラベシクルの調製は、例えば水相中で脂肪酸モノグリセリドを含有する油相混合物を物理的に撹拌せしめることにより行なわれる。このような方法としては、たとえば、脂肪酸モノグリセリド又はこれを含有する油相混合物をジクロロメタン、クロロホルム、アセトン等の有機溶媒に溶解した後、回転容器中で溶媒を留去して脂肪層を乾固させ(油相)、水又は適当な水溶液(水相)を添加し、物理的に撹拌して水相中に徐々に油相を分散・混合させることによって、本発明に用いるラメラベシクルの分散液を調製することができる(薄相法)。また別法として、水相を加熱して溶融混合した後、同程度の温度に保持され溶解された0.1〜15%程度の濃度の脂肪酸モノグリセリド又はこれを含有する油相混合物を添加し、物理的に油相を水相に分散・混合させ本発明に用いるラメラベシクルの分散液を調製することができる。上記加熱温度としては、40〜100℃、さらに45〜80℃が好ましく、50〜70℃が特に好ましい。   Such lamellar vesicles are prepared, for example, by physically stirring an oil phase mixture containing fatty acid monoglycerides in an aqueous phase. As such a method, for example, a fatty acid monoglyceride or an oil phase mixture containing the fatty acid monoglyceride is dissolved in an organic solvent such as dichloromethane, chloroform or acetone, and then the solvent is distilled off in a rotating container to dry the fat layer. (Oil phase), water or a suitable aqueous solution (aqueous phase) is added, and the oil phase is gradually dispersed and mixed in the aqueous phase by physically stirring, thereby dispersing the lamella vesicle dispersion used in the present invention. Can be prepared (thin phase method). Alternatively, after the water phase is heated and melted and mixed, a fatty acid monoglyceride having a concentration of about 0.1 to 15%, which is kept at the same temperature and dissolved, or an oil phase mixture containing the same is added, A dispersion of lamellar vesicles used in the present invention can be prepared by physically dispersing and mixing an oil phase in an aqueous phase. As said heating temperature, 40-100 degreeC, Furthermore, 45-80 degreeC is preferable, and 50-70 degreeC is especially preferable.

なお、粒子径の小さなラメラベシクルを得る為には、従来、物理的撹拌時の回転速度やせん断力を高める、すなわちより高いエネルギーをかけてやることが好ましいとされていたが、このような方法では平均粒子径0.05〜1μm、さらに0.05〜0.5μm、特に0.1〜0.5μmの微粒子ラメラを得ることはできなかった。   In order to obtain a lamellar vesicle having a small particle size, it has been conventionally preferred to increase the rotational speed and shearing force during physical stirring, that is, to apply higher energy. Thus, fine particle lamellae having an average particle diameter of 0.05 to 1 μm, further 0.05 to 0.5 μm, particularly 0.1 to 0.5 μm could not be obtained.

一方、特定の脂質を膜構成成分として用いる、特にモノパルミチン酸を構成脂肪酸とする脂肪酸モノグリセリドを用い、Ca2+の非存在下で上記の薄膜法で調整することで、平均粒子径0.5μm以下の微粒子ラメラが得られることは知られていたが、工程が複雑な上、溶媒を留去できる回転容器等、特殊な機器を必要とする為、コストがかかる等の問題があり、現実的ではなかった。 On the other hand, by using a specific lipid as a membrane constituent, particularly a fatty acid monoglyceride having monopalmitic acid as a constituent fatty acid, and adjusting by the above thin film method in the absence of Ca 2+ , an average particle size of 0.5 μm Although it was known that the following fine particle lamellae could be obtained, the process was complicated and a special device such as a rotating container capable of distilling off the solvent was required. It wasn't.

本発明者等は、より容易に微粒子ラメラを調製する方法を検討した結果、従来行なわれていた少ない油相を多量の水相に分散する方法ではなく、意外にも従来よりも多量の油相混合物に水相を添加して撹拌する方法、より詳細には、多量の油相混合物を加熱して溶融混合した後、同程度、又は油相より低温に保持された水相を添加し、物理的に撹拌して油相中に徐々に水相を分散・混合させることによって、0.05〜1μm、さらに0.05〜0.5μm、特に0.1〜0.5μmの微粒子ラメラ分散液を調製できることを見出した。   As a result of studying a method for preparing a fine particle lamella more easily, the present inventors have not unexpectedly conducted a method for dispersing a small oil phase in a large amount of water phase, but surprisingly a larger amount of oil phase than in the past. A method in which the aqueous phase is added to the mixture and stirred. More specifically, after heating and melt-mixing a large amount of the oil phase mixture, an aqueous phase kept at the same level or at a lower temperature than the oil phase is added, and the physical phase is added. By stirring and stirring, the aqueous phase is gradually dispersed and mixed in the oil phase so that a fine particle lamellar dispersion of 0.05 to 1 μm, further 0.05 to 0.5 μm, especially 0.1 to 0.5 μm can be obtained. It was found that it can be prepared.

当該調製方法における油相濃度としては、全量の20〜40%程度が好ましい。従って、20〜40重量部の油相成分に60〜80重量部の水相成分を添加することになる。また、油相としては、パルミチン酸、ステアリン酸、及びミリスチン酸の1種又は2種以上を構成脂肪酸とする脂肪酸モノグリセリドが好ましく、特にこれらを併用することが好ましい。油相及び水相の温度は、混合時の温度として50〜80℃、さらに52〜78℃が好ましく、57〜63℃が特に好ましい。或いは、50〜90℃、好ましくは70〜80℃の条件下に保った油相と、30〜80℃、好ましくは40〜50℃の条件下に保った水相を混合して行うこともできる。当該方法であれば、得られたラメラベシクルの50%以上が0.5μm以下でほぼ均質な粒子径を有する、微粒子ラメラベシクルを得ることができる。   The oil phase concentration in the preparation method is preferably about 20 to 40% of the total amount. Therefore, 60 to 80 parts by weight of the water phase component is added to 20 to 40 parts by weight of the oil phase component. Moreover, as an oil phase, the fatty acid monoglyceride which uses 1 type, or 2 or more types of a palmitic acid, a stearic acid, and myristic acid as a constituent fatty acid is preferable, and it is preferable to use these together especially. The temperature of the oil phase and the water phase is preferably 50 to 80 ° C., more preferably 52 to 78 ° C., and particularly preferably 57 to 63 ° C. as the temperature during mixing. Alternatively, an oil phase maintained at 50 to 90 ° C., preferably 70 to 80 ° C., and an aqueous phase maintained at 30 to 80 ° C., preferably 40 to 50 ° C., can be mixed and carried out. . According to this method, it is possible to obtain fine particle lamellar vesicles in which 50% or more of the obtained lamellar vesicles have a substantially uniform particle diameter of 0.5 μm or less.

何れの調製方法においても、物理的分散には、例えば超音波乳化装置、高圧均一分散装置、ナノマイザー、ホモジナイザー、コロイドミル、マイクロフルイタイザー等を用いることが好ましい。さらに、水相中にCa2+が存在する状態で調整すると、多層膜ラメラベシクルを得ることができる。 In any preparation method, it is preferable to use, for example, an ultrasonic emulsification apparatus, a high-pressure uniform dispersion apparatus, a nanomizer, a homogenizer, a colloid mill, or a microfluidizer for physical dispersion. Furthermore, when it adjusts in the state in which Ca <2+> exists in a water phase, a multilayer film lamellar vesicle can be obtained.

また、本発明のラメラベシクルとしては、単層膜ラメラベシクル、多層膜ラメラベシクルいずれを用いてもよく、単層膜と多層膜のラメラベシクルを併用することもできる。   In addition, as the lamellar vesicle of the present invention, either a single layer film lamellar vesicle or a multilayer film lamellar vesicle may be used, and a single layer film and a multilayer film lamellar vesicle may be used in combination.

本発明の組成物中の粒子径の異なるラメラベシクルの配合比率は特に制限するものではなく、使用するラメラベシクルの活性等により適宜選択して行なえばよい。例えば平均粒子径0.05〜5μmのラメラベシクルと平均粒子径6〜30μmのラメラベシクルの配合比率は、重量比率として1:100〜100:1、さらに1:50〜50:1、特に1:20〜20:1とすることが好ましい。   The blending ratio of lamellar vesicles having different particle sizes in the composition of the present invention is not particularly limited, and may be appropriately selected depending on the activity of the lamellar vesicles used. For example, the blending ratio of lamella vesicles having an average particle diameter of 0.05 to 5 μm and lamella vesicles having an average particle diameter of 6 to 30 μm is 1: 100 to 100: 1, more preferably 1:50 to 50: 1, particularly 1: It is preferably 20 to 20: 1.

また、平均粒子径0.05〜5μmのラメラベシクルの場合には、1種でもよいが、0.05〜1μmのラメラベシクルと1〜5μmのラメラベシクルを併用してもよい。   In the case of a lamella vesicle having an average particle diameter of 0.05 to 5 μm, one kind may be used, but a 0.05 to 1 μm lamella vesicle and a 1 to 5 μm lamella vesicle may be used in combination.

また、本発明に用いる2種のラメラベシクルの水相成分中には、種々のアスコルビン酸塩、ビタミンAエステル、及びそれらの誘導体、乳酸菌培養上清、防腐剤、保湿剤、ヒアルロン酸等の水溶性高分子などの水溶性成分が含まれていてもよい。   In the aqueous phase components of the two types of lamellar vesicles used in the present invention, various ascorbates, vitamin A esters, and derivatives thereof, lactic acid bacteria culture supernatants, preservatives, humectants, hyaluronic acid, and other water-soluble substances Water-soluble components such as water-soluble polymers may be included.

本発明の外用剤組成物は、粒子径の異なるラメラベシクルを2種以上配合した組成物をそのまま使用してもよいが、本発明の効果を妨げない範囲で公知の外用剤成分、例えば水、アルコール類、油成分、界面活性剤、防腐剤、香料、色素、保湿剤、増粘剤、水溶性高分子、酸化防止剤、キレート剤、pH調整剤、発泡剤、顔料、紫外線吸収・散乱剤、紛体、ビタミン類、アミノ酸類、抗菌剤、植物抽出物、動物由来成分、微生物由来成分、微生物培養上清、海藻抽出物、各種薬剤、添加剤等を配合することができる。   As the external preparation composition of the present invention, a composition in which two or more types of lamella vesicles having different particle diameters are blended may be used as it is, but known external preparation components such as water, as long as the effects of the present invention are not hindered. Alcohols, oil components, surfactants, preservatives, fragrances, dyes, moisturizers, thickeners, water-soluble polymers, antioxidants, chelating agents, pH adjusters, foaming agents, pigments, UV absorbers / scattering agents Powders, vitamins, amino acids, antibacterial agents, plant extracts, animal-derived components, microorganism-derived components, microorganism culture supernatants, seaweed extracts, various drugs, additives and the like can be blended.

本発明の外用剤組成物は、常法により製造することができ、化粧水、乳液、保湿クリーム、クレンジングクリーム、洗顔クリーム、パック、美容液等の基礎化粧品、シャンプーやリンス等の頭髪用製品、入浴剤等の浴用化粧品、ファンデーション等のメイクアップ化粧品、日焼け止め等の特殊化粧品等、種々の形態とする事ができるが、皮膚化粧料とするのが好ましい。   The external preparation composition of the present invention can be produced by a conventional method, such as skin lotion, milky lotion, moisturizing cream, cleansing cream, facial cleansing cream, pack, cosmetic liquid and other basic cosmetics, hair products such as shampoo and rinse, Various forms such as bath cosmetics such as bath preparations, makeup cosmetics such as foundations, and special cosmetics such as sunscreens can be used, but skin cosmetics are preferred.

外用剤組成物へのラメラベシクルの配合量は特に制限されないが、外用剤組成物中に合計で0.01〜100重量%、さらに0.1〜90重量%とすることが好ましく、特に0.3〜80重量%が好ましい。   The blending amount of the lamella vesicle in the external preparation composition is not particularly limited, but is preferably 0.01 to 100% by weight, more preferably 0.1 to 90% by weight in the external preparation composition. 3 to 80% by weight is preferred.

次に実施例を挙げて本発明を詳細に説明するが、本発明はこれらに限定されるものではない。以下%は重量%を示す。   EXAMPLES Next, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these. Hereinafter, “%” represents “% by weight”.

製造例1
蒸留水1mLに対し、1%モノパルミチン、0.3%バチルアルコール及び0.1%コレステロールとなる量に各々の脂質を秤量し、脂質混合物Aを調整した。容器中で脂質混合物Aを乾固した後、10mMのCaCl2溶液を加え、60℃の温浴中で超音波処理(Branson sonifer250;Branson社製、20kHz、55W、10分間)を行った。得られた混合液を遠心処理にて上清を蒸留水に置換し、試料1を得た。
Production Example 1
Each lipid was weighed in an amount of 1% monopalmitin, 0.3% batyl alcohol and 0.1% cholesterol with respect to 1 mL of distilled water to prepare a lipid mixture A. After lipid mixture A was dried in a container, 10 mM CaCl 2 solution was added and sonication (Branson sonifer 250; Branson, 20 kHz, 55 W, 10 minutes) was performed in a 60 ° C. warm bath. The supernatant was replaced with distilled water by centrifuging the obtained mixture, and sample 1 was obtained.

製造例2
実施例1と同様に脂質混合物Aを調整し、容器中で乾固した後に蒸留水を加え、60℃の温浴中製造例1と同じ条件で超音波処理を行い、試料2を得た。
Production Example 2
Lipid mixture A was prepared in the same manner as in Example 1, and after drying in a container, distilled water was added and sonication was performed in a 60 ° C. warm bath under the same conditions as in Production Example 1 to obtain Sample 2.

製造例3
蒸留水1mLに対し、0.5%モノミリスチン、0.5%モノパルミチン、0.3%バチルアルコール及び0.1%コレステロールとなる量に各々の脂質を秤量し、脂質混合物Bを調整した。容器中で脂質混合物Bを乾固した後に蒸留水を加え、60℃の温浴中で製造例1と同じ条件で超音波処理を行い、試料3を得た。
Production Example 3
Each lipid was weighed to an amount of 0.5% monomyristin, 0.5% monopalmitin, 0.3% batyl alcohol and 0.1% cholesterol with respect to 1 mL of distilled water to prepare a lipid mixture B. Distilled water was added after the lipid mixture B was dried in a container, and sonication was performed in a warm bath at 60 ° C. under the same conditions as in Production Example 1 to obtain Sample 3.

製造例4
製造例1及び2で得られた試料1及び試料2を当量ずつ混合して、実施品1を得た。
Production Example 4
Sample 1 and sample 2 obtained in Production Examples 1 and 2 were mixed in an equivalent amount to obtain Example Product 1.

試験例1
ラメラベシクルの粒度分布
測定には、製造例1〜3で得られた試料1〜3を用い、常法に従い、各々のラメラベシクルの粒子分布を測定した。すなわち計測カップに試料を0.1〜1mL分散後直ちに室温にて下で島津レーザー回折式粒度分布計(SALD-2000;島津製作所製)を用いて測定した。結果を図1に示す。
Test example 1
The particle size distribution of the lamellar vesicles was measured by using the samples 1 to 3 obtained in Production Examples 1 to 3 and measuring the particle distribution of each lamellar vesicle according to a conventional method. That is, the sample was dispersed in a measuring cup in an amount of 0.1 to 1 mL and immediately measured at room temperature using a Shimadzu laser diffraction particle size distribution analyzer (SALD-2000; manufactured by Shimadzu Corporation). The results are shown in FIG.

図1に示したとおり、試料1の平均粒子径は10μmだが、粒度の分布は広範囲に及び、大きいものでは20〜30μmのものもあることが明らかとなった。それに対して試料2は平均粒子径が3μmで、粒度分布の幅は狭かった。試料3の粒度分布はさらに狭く、その平均粒子径は0.2μmであった。   As shown in FIG. 1, the average particle size of Sample 1 was 10 μm, but it was revealed that the particle size distribution was in a wide range, with some being 20 to 30 μm. In contrast, sample 2 had an average particle size of 3 μm and a narrow particle size distribution. Sample 3 had a narrower particle size distribution and an average particle size of 0.2 μm.

試験例2
皮膚の肥厚に及ぼす影響
試験には、製造例1〜2、及び4で得られた試料1及び2、並びに実施品1を用いた。ヘアレスマウス(Hr-1:Hos、雌、7週令)に40mJ/cm2/日の紫外線を1日1回、4日間照射した。各照射直後に、試料1、2及び実施品1を各々200μlずつ背部皮膚に連日塗布した(n=4〜6)。試料としては蒸留水を用いた。実験終了日(照射4日目)に皮膚を剥がし、皮膚の厚さをデジマジック・インジケータ543(三豊社製)を用いて測定した。結果を図2に示す。
Test example 2
Influence on skin thickening For the test, Samples 1 and 2 obtained in Production Examples 1 and 2 and 4 and Example 1 were used. Hairless mice (Hr-1: Hos, female, 7 weeks old) were irradiated with 40 mJ / cm 2 / day of ultraviolet rays once a day for 4 days. Immediately after each irradiation, 200 μl each of Samples 1 and 2 and Example 1 were applied to the back skin every day (n = 4-6). Distilled water was used as a sample. The skin was peeled off on the experiment end date (irradiation day 4), and the skin thickness was measured using a Digimagic indicator 543 (manufactured by Mitoyo). The results are shown in FIG.

図2に示したとおり、平均粒子径10μm、及び平均粒子径3μmのいずれのラメラベシクルも、紫外線による皮膚の肥厚を抑制傾向は示したが、有意な抑制効果は示さなかった。一方、これらの粒子径を併用することで、単独で使用した場合に比べ相乗的に抑制することがわかった。   As shown in FIG. 2, both lamella vesicles having an average particle diameter of 10 μm and an average particle diameter of 3 μm showed a tendency to suppress skin thickening due to ultraviolet rays, but did not show a significant inhibitory effect. On the other hand, it was found that the combined use of these particle sizes suppresses synergistically as compared with the case of using them alone.

試験例3
皮膚弾力性に及ぼす影響
試験には、製造例1〜2、及び4で得られた試料1及び2、並びに実施品1を用いた。試験例2と同様に紫外線照射及び試料の塗布を行い、Cutometer SM575(C+K社製)を用い、直径2mmの計測センサーを用いて、吸引圧50mbarで皮膚弾力性を測定した。結果を図3に示す。
Test example 3
Influence on skin elasticity The samples 1 and 2 obtained in Production Examples 1 and 2 and 4 and the product 1 were used for the test. In the same manner as in Test Example 2, ultraviolet irradiation and sample application were performed, and skin elasticity was measured at a suction pressure of 50 mbar using a Cutometer SM575 (manufactured by C + K) and a measuring sensor having a diameter of 2 mm. The results are shown in FIG.

図3に示したとおり、平均粒子径10μm、及び平均粒子径3μmのいずれのラメラベシクルも、紫外線による皮膚の弾力性の低下を抑制できなかった。一方、これらの粒子径を併用した場合は、皮膚弾力性の低下は全く生じず、極めて優れた抑制効果が得られることがわかった。   As shown in FIG. 3, none of the lamellar vesicles having an average particle diameter of 10 μm and an average particle diameter of 3 μm was able to suppress a decrease in skin elasticity due to ultraviolet rays. On the other hand, it was found that when these particle sizes were used in combination, the skin elasticity was not lowered at all and an extremely excellent suppression effect was obtained.

試験例4
ラメラベシクルの粒子径に及ぼす脂質量の影響
脂肪酸モノグリセリド(モノステアリン:モノパルミチン=7:3)、バチルアルコール、及びコレステロールを表1の比率で混合し、脂質混合物を得た。得られた脂質混合物を、各々容器内に投与し、75℃下で溶融した後、撹拌機(ポリトロンホモジナイザー PT3000型;KINEMATICA社製、6000rpm、1分)で撹拌した。次いで45℃に加温した精製水を投入し、全体を100%とした後、撹拌機を用いて、6000rpm、2分間撹拌し、均一化した。均一化後撹拌下で(1000rpm)水浴により冷却を開始し、32℃まで冷却して試料4〜7を得た。得られた試料の状態を肉眼で観察し、試料の状態を確認した。また得られたラメラベシクル混合物を蒸留水により25倍に希釈し、偏光顕微鏡下(10×40倍)でラメラの状態を比較した。
Test example 4
Effect of Lipid Amount on Particle Size of Lamella Vesicle Fatty acid monoglyceride (monostearin: monopalmitin = 7: 3), batyl alcohol, and cholesterol were mixed at a ratio shown in Table 1 to obtain a lipid mixture. The obtained lipid mixture was each administered into a container, melted at 75 ° C., and then stirred with a stirrer (polytron homogenizer PT3000 type; manufactured by KINEMATICA, 6000 rpm, 1 minute). Next, purified water heated to 45 ° C. was added to make the whole 100%, and then stirred using a stirrer at 6000 rpm for 2 minutes for homogenization. After homogenization, cooling was started with a water bath under stirring (1000 rpm) and cooled to 32 ° C. to obtain Samples 4 to 7. The state of the obtained sample was observed with the naked eye to confirm the state of the sample. The obtained lamella vesicle mixture was diluted 25 times with distilled water, and the lamella states were compared under a polarizing microscope (10 × 40 times).

Figure 2005047904
Figure 2005047904

Figure 2005047904
Figure 2005047904

表2に示したように、試料4、5に比べ、試料6、7のラメラベシクルは比較的粒子が均一で、特に試料6は組成物の状態も良好であった。一方、試料7は得られるラメラベシクルの粒子径は最も小さかったが、試料6に比べて組成物の状態が悪かった。
また試料6のラメラベシクルについて粒子分布を測定した。すなわち、試料を4000倍希釈した条件下でFPIA−2100(SYSMEX社製)を用いて測定し、平均粒子径を求めた結果、試料6の平均粒子径は0.45μmであった。従って、20〜40重量部の高濃度の脂質に60〜80重量部の水相を添加して撹拌することにより平均粒子径0.05〜1μmの状態の良好なラメラベシクルが得られることがわかった。
As shown in Table 2, the lamella vesicles of Samples 6 and 7 had relatively uniform particles as compared with Samples 4 and 5, and Sample 6 particularly had a good composition. On the other hand, sample 7 had the smallest particle diameter of the resulting lamellar vesicle, but the composition was inferior to sample 6.
The particle distribution of the lamella vesicle of Sample 6 was measured. That is, the sample was measured using FPIA-2100 (manufactured by SYSMEX) under the condition where the sample was diluted 4000 times, and the average particle size was determined. As a result, the average particle size of Sample 6 was 0.45 μm. Therefore, it is understood that a good lamellar vesicle having an average particle size of 0.05 to 1 μm can be obtained by adding 60 to 80 parts by weight of an aqueous phase to 20 to 40 parts by weight of a high-concentration lipid and stirring. It was.

試験例5
ラメラベシクルの粒子径に及ぼす撹拌速度及び温度の影響
脂肪酸モノグリセリド(モノステアリン:モノパルミチン=7:3)、バチルアルコール、及びコレステロールを製造例1と同じ比率で混合し、脂質混合物を得た。得られた脂質混合物を全量の28%となるよう秤量して容器内に投与し、表3に記載した温度下で溶融した。次いで表3に示した温度に加温した精製水を投入し、全体を100%とした後、撹拌機を用いて撹拌し、均一化した。均一化後撹拌下で(1000rpm、又は500rpm)水浴により冷却を開始し、32℃まで冷却して試料8〜11を得た。得られた試料の状態を肉眼で観察し、試料の状態を確認した。また得られたラメラベシクル混合物を蒸留水により25倍に希釈し、試験例4と同じ条件下でラメラの状態及びラメラベシクルの粒子分布を測定した。結果を表4に示す。
Test Example 5
Effect of stirring speed and temperature on particle diameter of lamellar vesicle Fatty acid monoglyceride (monostearin: monopalmitin = 7: 3), batyl alcohol, and cholesterol were mixed in the same ratio as in Production Example 1 to obtain a lipid mixture. The obtained lipid mixture was weighed to 28% of the total amount, administered into a container, and melted at the temperature described in Table 3. Next, purified water heated to the temperature shown in Table 3 was added to make the whole 100%, and the mixture was stirred and homogenized using a stirrer. After homogenization, cooling was started with a water bath under stirring (1000 rpm or 500 rpm), and cooled to 32 ° C. to obtain Samples 8 to 11. The state of the obtained sample was observed with the naked eye to confirm the state of the sample. The obtained lamella vesicle mixture was diluted 25 times with distilled water, and the lamella state and the particle distribution of the lamella vesicle were measured under the same conditions as in Test Example 4. The results are shown in Table 4.

Figure 2005047904
Figure 2005047904

Figure 2005047904
Figure 2005047904

表4に示したように、試料8〜10はいずれもラメラベシクルの状態、及びラメラベシクルの粒子径は試料6とほぼ同一であり、ラメラベシクル製造開始時の撹拌速度はラメラベシクルの粒子径や状態に影響しなかった。また、試料11もラメラベシクルの状態、及びラメラベシクルの粒子径は試料6とほぼ同一であり、製造時の油相の温度が40℃以上、或いは撹拌時の油相成分と水相成分の混合物の温度が50℃以上であれば、平均0.45μmのラメラベシクルが得られることがわかった。   As shown in Table 4, all of the samples 8 to 10 are in a lamellar vesicle state and the particle size of the lamellar vesicle is almost the same as that of the sample 6, and the stirring speed at the start of the production of the lamellar vesicle is the particle size of the lamellar vesicle. The condition was not affected. Sample 11 is also in the state of lamellar vesicles and the particle size of lamellar vesicles is almost the same as sample 6, and the temperature of the oil phase during production is 40 ° C. or higher, or a mixture of oil phase components and water phase components during stirring. It was found that a lamellar vesicle having an average of 0.45 μm can be obtained when the temperature of is 50 ° C. or higher.

製造例5
下記成分のうち、1〜3各々の脂質を秤量し、60〜85℃で加熱溶解して脂質混合物Dを得た。一方、4、5を秤量、混合し60〜85℃で加熱溶解して水相成分を得た。得られた水相成分に脂質混合物を投入し撹拌機(ポリトロンホモジナイザー PT3000型;KINEMATICA社製、6000rpm、1分)で撹拌し、試料12を得た。
Production Example 5
Among the following components, 1 to 3 lipids were weighed and dissolved by heating at 60 to 85 ° C. to obtain a lipid mixture D. On the other hand, 4 and 5 were weighed and mixed, and dissolved by heating at 60 to 85 ° C. to obtain an aqueous phase component. A lipid mixture was added to the obtained aqueous phase component and stirred with a stirrer (Polytron homogenizer PT3000 type; manufactured by KINEMATICA, 6000 rpm, 1 minute) to obtain Sample 12.

1.モノパルミチン 5.0(重量%)
2.バチルアルコール 1.5
3.コレステロール 0.5
4.塩化カルシウム 0.1
5.精製水 92.9
1. Monopalmitin 5.0 (wt%)
2. Batyl alcohol 1.5
3. Cholesterol 0.5
4). Calcium chloride 0.1
5. Purified water 92.9

製造例6
製造例1及び5で得られた試料1及び12を当量ずつ混合して、実施品2を得た。
Production Example 6
Samples 1 and 12 obtained in Production Examples 1 and 5 were mixed in an equivalent amount to obtain Example Product 2.

製造例7
製造例1、2及び5で得られた試料1、試料2及び試料12を当量ずつ混合して、実施品3を得た。
Production Example 7
Sample 1, Sample 2, and Sample 12 obtained in Production Examples 1, 2, and 5 were mixed in an equivalent amount to obtain Example Product 3.

試験例6
ラメラベシクルの粒度分布
測定には、製造例1、2及び4で得られた試料1、試料2及び試料12を用い、試験例1と同様にラメラベシクルの粒度分布を測定した。結果を図4に示す。
図4に示したとおり、試料12の平均粒子径は0.1μmであった。
Test Example 6
The particle size distribution of lamella vesicles was measured in the same manner as in Test Example 1 using Sample 1, Sample 2 and Sample 12 obtained in Production Examples 1, 2, and 4. The results are shown in FIG.
As shown in FIG. 4, the average particle size of Sample 12 was 0.1 μm.

試験例7
皮膚の肥厚に及ぼす影響
試験には、製造例2及び7で得られた試料2及び実施品3を用い、試験例2と同様に皮膚の厚さを測定した。結果を図5に示す。
図5に示したとおり、平均粒子径10μm、3μm及び0.1μmのラメラベシクルを併用することで、紫外線による皮膚の肥厚に対し、優れた抑制効果が得られることがわかった。
Test Example 7
Influence on skin thickening For the test, the thickness of the skin was measured in the same manner as in Test Example 2 using Sample 2 and Example 3 obtained in Production Examples 2 and 7. The results are shown in FIG.
As shown in FIG. 5, it was found that an excellent inhibitory effect on the thickening of the skin caused by ultraviolet rays can be obtained by using lamella vesicles having an average particle size of 10 μm, 3 μm and 0.1 μm in combination.

試験例8
皮膚弾力性に及ぼす影響
試験には、製造例1及び7で得られた試料1及び実施品3を用い、試験例3と同様に皮膚弾力性を測定した。結果を図6に示す。
図6に示したとおり、平均粒子径10μm、3μm及び0.1μmのラメラベシクルを併用することで、皮膚弾力性の低下は生じず、優れた抑制効果が得られることがわかった。
Test Example 8
Influence on Skin Elasticity For the test, skin elasticity was measured in the same manner as in Test Example 3, using Sample 1 and Example 3 obtained in Production Examples 1 and 7. The results are shown in FIG.
As shown in FIG. 6, it was found that by using lamella vesicles having an average particle size of 10 μm, 3 μm and 0.1 μm in combination, the skin elasticity did not decrease and an excellent suppression effect was obtained.

処方例1 保湿クリーム
下記成分のうち、油相成分(1〜13)を加熱溶解し、また同様に水相成分(14〜22)も加熱溶解する。前記の加熱した水相に油相を混合しホモジナイザーで撹拌しその後冷却する。冷却途中で添加成分(23〜32)を投入、混合して保湿クリームを得た。
Formulation Example 1 Moisturizing cream Among the following components, the oil phase component (1-13) is dissolved by heating, and the water phase component (14-22) is also dissolved by heating. The oil phase is mixed with the heated aqueous phase, stirred with a homogenizer, and then cooled. During the cooling, the additive components (23 to 32) were added and mixed to obtain a moisturizing cream.

1.スクワラン 4.30%(重量%)
2.2−エチルヘキサン酸セチル 4.50
3.ミリスチン酸オクチルドデシル 4.50
4.重質流動イソパラフィン 4.00
5.サラシミツロウ 2.40
6.ステアリン酸 2.40
7.ステアリン酸バチル 1.20
8.ベヘニルアルコール 1.20
9.モノステアリン酸ポリエチレングリコール(40) 0.50
10.グリチルレチン酸ステアリル 0.10
11.酢酸dl−α−トコフェロール 0.10
12.天然ビタミンE 0.001
13.メチルポリシロキサン 0.20
14.精製水 15.879
15.アクリル酸・メタクリル酸共重合体 3.00
16.ホエイ(2) 19.90
17.グリセリン 10.00
18.ポリオキシエチレンメチルグルコシド 1.50
19.1.3−ブチレングリコール 7.00
20.カンゾウ抽出物 0.12
21.エデト酸ニナトリウム 0.10
22.パラオキシ安息香酸エステル 0.20
23.KOH 0.20
24.ヒアルロン酸Na液(0.6%) 4.90
25.2−メタクロイルオキシエチルホスコリン・メタクリル酸ブチル
共重合体 3.00
26.ブクリョウエキス 0.10
27.ニンジンエキス 0.05
28.酵母エキス 0.05
29.ロイヤルゼリー 0.05
30.グルコン酸クロルヘキシジン 0.05
31.ラメラベシクル組成物(試料12、平均粒子径10μm)
8.00
32.ラメラベシクル組成物(試料6、平均粒子径0.45μm)
0.50
1. Squalane 4.30% (% by weight)
2.2 Cetyl 2-ethylhexanoate 4.50
3. Octyldodecyl myristate 4.50
4). Heavy liquid isoparaffin 4.00
5. White beeswax 2.40
6). Stearic acid 2.40
7. Batyle stearate 1.20
8). Behenyl alcohol 1.20
9. Polyethylene glycol monostearate (40) 0.50
10. Stearyl glycyrrhetinate 0.10
11. Dl-α-tocopherol acetate 0.10
12 Natural vitamin E 0.001
13. Methylpolysiloxane 0.20
14 Purified water 15.879
15. Acrylic acid / methacrylic acid copolymer 3.00
16. Whey (2) 19.90
17. Glycerin 10.00
18. Polyoxyethylene methyl glucoside 1.50
19.1.3-Butylene glycol 7.00
20. Licorice extract 0.12
21. Edetate disodium 0.10
22. P-Hydroxybenzoate 0.20
23. KOH 0.20
24. Hyaluronic acid Na solution (0.6%) 4.90
25.2-Methacryloyloxyethylphoscholine / butyl methacrylate copolymer 3.00
26. Bukuryu extract 0.10
27. Carrot extract 0.05
28. Yeast extract 0.05
29. Royal Jelly 0.05
30. Chlorhexidine gluconate 0.05
31. Lamella vesicle composition (sample 12, average particle size 10 μm)
8.00
32. Lamella vesicle composition (sample 6, average particle size 0.45 μm)
0.50

得られた保湿クリームは、使用感、保湿等に優れたクリームであった。   The obtained moisturizing cream was excellent in feeling of use, moisturizing and the like.

ラメラベシクルの粒度分布を示す図である。It is a figure which shows the particle size distribution of a lamella vesicle. 各試料の皮膚の肥厚に及ぼす作用を示す図である。It is a figure which shows the effect | action which acts on the thickening of the skin of each sample. 各試料の皮膚弾力性に及ぼす作用を示す図である。It is a figure which shows the effect | action which acts on the skin elasticity of each sample. ラメラベシクルの粒度分布を示す図である。It is a figure which shows the particle size distribution of a lamella vesicle. 各試料の皮膚の肥厚に及ぼす作用を示す図である。It is a figure which shows the effect | action which acts on the thickening of the skin of each sample. 各試料の皮膚弾力性に及ぼす作用を示す図である。It is a figure which shows the effect | action which acts on the skin elasticity of each sample.

Claims (4)

脂肪酸モノグリセリドを主成分とするラメラベシクルであって、平均粒子径0.05〜5μmのラメラベシクルと平均粒子径6〜30μmラメラベシクルとを含有することを特徴とする外用剤組成物。   An external preparation composition comprising a lamellar vesicle mainly composed of a fatty acid monoglyceride and comprising a lamellar vesicle having an average particle size of 0.05 to 5 µm and an lamellar vesicle having an average particle size of 6 to 30 µm. 皮膚化粧料組成物である請求項1記載の外用剤組成物。   The external preparation composition according to claim 1, which is a skin cosmetic composition. 脂肪酸モノグリセリドが、炭素数8〜20の飽和又は不飽和脂肪酸モノグリセリドである請求項1又は2記載の外用剤組成物。   The external preparation composition according to claim 1 or 2, wherein the fatty acid monoglyceride is a saturated or unsaturated fatty acid monoglyceride having 8 to 20 carbon atoms. 脂肪酸モノグリセリドを主成分とする脂質成分20〜40重量部に水相成分60〜80重量部を添加して撹拌することを特徴とする平均粒子径0.05〜1μmのラメラベシクルの製造法。   A method for producing a lamellar vesicle having an average particle size of 0.05 to 1 µm, wherein 60 to 80 parts by weight of an aqueous phase component is added to 20 to 40 parts by weight of a lipid component mainly composed of a fatty acid monoglyceride and stirred.
JP2004207104A 2003-07-14 2004-07-14 External preparation composition Active JP4592347B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004207104A JP4592347B2 (en) 2003-07-14 2004-07-14 External preparation composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003196364 2003-07-14
JP2004207104A JP4592347B2 (en) 2003-07-14 2004-07-14 External preparation composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010173504A Division JP5329489B2 (en) 2003-07-14 2010-08-02 External preparation composition

Publications (2)

Publication Number Publication Date
JP2005047904A true JP2005047904A (en) 2005-02-24
JP4592347B2 JP4592347B2 (en) 2010-12-01

Family

ID=34277290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004207104A Active JP4592347B2 (en) 2003-07-14 2004-07-14 External preparation composition

Country Status (1)

Country Link
JP (1) JP4592347B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007254353A (en) * 2006-03-23 2007-10-04 Yakult Honsha Co Ltd Noble metal colloid-including lamella structure, its dispersion, cosmetic containing the same and method for producing the dispersion
JP2010120855A (en) * 2008-11-17 2010-06-03 Yakult Honsha Co Ltd Humectant and cosmetic containing the same
JP2010120873A (en) * 2008-11-19 2010-06-03 Yakult Honsha Co Ltd Skin external preparation
WO2016072435A1 (en) * 2014-11-06 2016-05-12 日本メナード化粧品株式会社 Agent for maintaining stem cells in undifferentiated state and agent for promoting growth thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04338311A (en) * 1991-05-16 1992-11-25 Yakult Honsha Co Ltd Humectant
JPH0859449A (en) * 1994-08-26 1996-03-05 Yakult Honsha Co Ltd Humectant and cosmetic containing the same
JPH11510155A (en) * 1995-08-02 1999-09-07 プロチュース モレキュラー デザイン リミテッド Method of treatment
JP2000239140A (en) * 1999-02-17 2000-09-05 Yakult Honsha Co Ltd Preparation for external use for skin
JP2001518886A (en) * 1997-04-03 2001-10-16 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Oil-in-water emulsion for reconstructing the lamellarity of lipid structure of damaged skin
JP2002145751A (en) * 2000-11-02 2002-05-22 Yakult Honsha Co Ltd Skin care preparation containing ascorbic acids

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04338311A (en) * 1991-05-16 1992-11-25 Yakult Honsha Co Ltd Humectant
JPH0859449A (en) * 1994-08-26 1996-03-05 Yakult Honsha Co Ltd Humectant and cosmetic containing the same
JPH11510155A (en) * 1995-08-02 1999-09-07 プロチュース モレキュラー デザイン リミテッド Method of treatment
JP2001518886A (en) * 1997-04-03 2001-10-16 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Oil-in-water emulsion for reconstructing the lamellarity of lipid structure of damaged skin
JP2000239140A (en) * 1999-02-17 2000-09-05 Yakult Honsha Co Ltd Preparation for external use for skin
JP2002145751A (en) * 2000-11-02 2002-05-22 Yakult Honsha Co Ltd Skin care preparation containing ascorbic acids

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007254353A (en) * 2006-03-23 2007-10-04 Yakult Honsha Co Ltd Noble metal colloid-including lamella structure, its dispersion, cosmetic containing the same and method for producing the dispersion
JP2010120855A (en) * 2008-11-17 2010-06-03 Yakult Honsha Co Ltd Humectant and cosmetic containing the same
JP2010120873A (en) * 2008-11-19 2010-06-03 Yakult Honsha Co Ltd Skin external preparation
WO2016072435A1 (en) * 2014-11-06 2016-05-12 日本メナード化粧品株式会社 Agent for maintaining stem cells in undifferentiated state and agent for promoting growth thereof
JP2016086757A (en) * 2014-11-06 2016-05-23 日本メナード化粧品株式会社 Agent for maintaining undifferentiated state of stem cell and agent for promoting its proliferation
US10259772B2 (en) 2014-11-06 2019-04-16 Nippon Menard Cosmetic Co., Ltd. Agents for maintaining undifferentiated state and promoting proliferation of stem cells

Also Published As

Publication number Publication date
JP4592347B2 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
JP3641152B2 (en) Topical skin preparation
JP4758915B2 (en) Multilamellar liposome and production method thereof
JP4527530B2 (en) Vesicle dispersion and cosmetics containing the same
JP5254645B2 (en) Vesicle composition and external preparation for skin containing the vesicle composition
JP6588568B2 (en) Composition containing bicell structure
JP6231624B2 (en) Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected
KR101633639B1 (en) Nano gel emulsion having similar structure with cell membrane using self-assembled gel characteristics and osmetic composition using the same
JP2010184908A (en) Emulsified composition and cosmetic comprising the same, and skin care preparation for external use
WO2012017733A1 (en) Skin cosmetic
JP2005179313A (en) Method for producing base agent for skin cosmetic, and skin cosmetic
KR20160082054A (en) Emulsifier-Free Cosmetic Composition of the Oil-in-Water Emulsion Type and Preparation Method Thereof
JP5483865B2 (en) Topical skin preparation
JP4592347B2 (en) External preparation composition
KR101694987B1 (en) Oil-in-water solubilized cosmetic composition comprising hydrolyzed jojoba ester oil
JP2020019764A (en) Composition containing bicell structure
JP5329489B2 (en) External preparation composition
JP5602084B2 (en) Moisturizer and cosmetic containing the same
KR20170045430A (en) Liposome composition containg vinegar, preparation method thereof, and cosmetic composition comprising the same
KR20150078137A (en) Cosmetic composition for improving skin wrinkle
JP5539785B2 (en) Moisturizer and cosmetics containing the same
JP2005179238A (en) Skin care preparation
KR100501309B1 (en) Manufacturing Method of Nano-emulsified Cosmetic Composition Containing Arbutin
KR102653968B1 (en) Method for manufacturing cosmetic composition with improved stability comprising high content of ceramide
KR102381622B1 (en) Stabilizing method of rice bran wax and cosmetic composition containing the stabilized rice bran wax
TWI718574B (en) Compositions containing linoleic acid

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100824

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100914

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

R151 Written notification of patent or utility model registration

Ref document number: 4592347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3